ReviewLeukemia2007
Chronic graft-versus-host disease in the era of reduced-intensity conditioning.
Review in Leukemia, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies.Leukemia & lymphoma · 2014Trial
- Biology of chronic graft-World journal of transplantation · 2016Review
- Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015Observational
- Risk factors and organ involvement of chronic GVHD in Japan.Bone marrow transplantation · 2014Article
- Immune Reactions following Cord Blood Transplantations in Adults.Stem cells international · 2011Article
- Non-myeloablative allogeneic hematopoietic stem cell transplantation.Seminars in oncology nursing · 2009Review
- Clinical characteristics of chronic graft-versus-host disease following umbilical cord blood transplantation for adults.Bone marrow transplantation · 2008Article
- Murine models of chronic graft-versus-host disease: insights and unresolved issues.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2008Review
- Mesenchymal stem cells of cord blood origin are effective at preventing but not treating graft-versus-host disease.Leukemia · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In the past decade the field of hematopoietic stem cell transplantation has entered a new era with the introduction of reduced intensity conditioning (RIC) regimens. The impact of RIC on the incidence of chronic graft-versus-host disease (GVHD) has not been evaluated systematically. Factors confounding such analyses include short follow-up in studies, absence of prospective comparison trials, use of a variety of RIC regimens, lack of uniform GVHD prophylaxis and lack of rigorous criteria for the diagnosis and staging of chronic GVHD. This review discusses factors that appear to influence the incidence and clinical presentation of chronic GVHD in the RIC transplantation era. Overall, RIC seems to decrease the incidence and severity of acute GVHD through day 100 post-transplant when compared to conventional conditioning; however, there is little evidence to suggest that chronic GVHD is reduced after RIC. For the more definitive assessments of chronic GVHD after RIC it will be important to study this question in prospective comparison trials with long duration of follow-up. The recent National Institutes of Health chronic GVHD consensus project recommendations provide now the critically needed standardized guidelines for the diagnosis, classification and staging of chronic GVHD.
Indexed as
Identifiers
17377592What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.